EVis Bioscience AG, a Zürich-based ETH spin-off, has secured $469,313 in investment capital from investors. This funding round marks a significant step for the biotechnology company as it continues to advance its innovative work in gene delivery systems for targeted and personalized medicine. The investment underscores confidence in EVis Bioscience’s approach to addressing complex medical challenges in the field.
The company specializes in developing advanced gene delivery platforms, including extracellular vesicles, synthetic lipid nanoparticles, and their hybrids. EVis Bioscience’s core mission is to offer an alternative to traditional viral vectors for the treatment of genetic disorders, aiming for safer and more precise therapeutic applications. Beyond its internal research, the company also provides sub-licenses of its proprietary delivery vehicles to pharmaceutical companies and research laboratories for specific medical applications.
The newly raised capital will be strategically deployed to accelerate EVis Bioscience AG's research and development initiatives. This includes further enhancing its sophisticated laboratory capabilities and expanding its scientific team to expedite the development of its cutting-edge technologies. The funding is critical for progressing the company’s platform towards potential clinical applications and broadening its intellectual property portfolio.
Looking ahead, EVis Bioscience AG plans to leverage this investment to solidify its position as a key innovator in the gene therapy landscape. The company aims to continue refining its gene delivery systems, driving forward its mission to provide effective and personalized treatments for genetic disorders, ultimately contributing to advancements in global healthcare.
